What Is ParkinZheimer? Why Is It Important? And How To Detect It Early.
Alzheimer'sParkinson'sParkinZheimer

What Is ParkinZheimer?

By June 24, 2020 No Comments

Essential Understanding For Early Testing Of Parkinson’s & Alzheimer’s

 

ParkinZheimer

Decades of research on Alzheimer’s and Parkinson’s have led us to a unique perspective—these are closely related diseases on the same spectrum.

We call it—the ParkinZheimer Spectrum.

Our unique Parkinzheimer viewpoint is the pillar of our scientific discovery in detecting misfolded Synuclein, a prion biomarker known to drive Parkinson’s disease, Alzheimer’s disease (up to 40% of Alzheimer’s patients) and other neurodegenerative diseases.

Recently, the FDA awarded Amprion a Breakthrough Device Designation for its technology in detecting misfolded Synuclein. We are thrilled to receive such a distinct honor and are working to apply the same assay in detecting misfolded Abeta and Tau, essential biomarkers related to Alzheimer’s and other diseases on the ParkinZheimer Spectrum.

In this article, we’ll examine why the ParkinZheimer theory is paramount in our work and in paving the way to find a cure.

“Alzheimer’s and Parkinson’s are diseases on a spectrum. We call it the ParkinZheimer Spectrum.”

Why Is ParkinZheimer Important? 

Consider this: During the past three decades, Alzheimer’s and Parkinson’s drug development and clinical trials have failed to find a cure despite hefty spending of more than US$30 billion worldwide.

And yet, the need to find a cure for Alzheimer’s and Parkinson’s has never been greater. The number of people in the US diagnosed with Alzheimer’s and Parkinson’s is currently estimated at 5.8 million and 1 million, respectively.

These numbers will increase nearly threefold by 2050 without effective treatments, according to The Alzheimer’s Association and Parkinson’s Foundation (Parkinson.org).

These organizations also project that the combined cost of caring for Alzheimer’s and Parkinson’s patients in the US will rise to approximately $1.3 trillion by 2050, threatening our economy.

 

This short video gives an in-depth understanding of the global health challenge we face.

We believe the lack of successful drug development is largely due to the way Alzheimer’s and Parkinson’s are perceived as two distinct diseases. Therefore these diseases have been placed in separate silos.

To accelerate successful drug treatments, our scientists have gained significant new ground in an innovative technique to diagnose Alzheimer’s and Parkinson’s by tracking the biomarkers, aka misfolded protein or prions, of both diseases. This has led us to the ParkinZheimer Spectrum thesis

Watch this short video to learn more about Prions and the role they play in ParkinZheimer

Thanks to advancements in molecular biology, for the first time in history, we are empowered to detect these biomarkers that drive the ParkinZheimer Spectrum. Early and with certainty. Why this change in paradigm?

“Because this new thinking gives us a new lens in looking at an old problem
where advancement had been impossible.”

At Amprion, our goal is to share the ParkinZheimer approach in analyzing, diagnosing Alzheimer’s and Parkinson’s—elusive diseases that have mystified us for the past centuries.  Accurate early detection is the pathway to accelerate drug development.  Ultimately, our objective is to find a cure before we lose another generation.

Science has advanced, and the time has come to expand our horizons in looking at Alzheimer’s and Parkinson’s as ParkinZheimer.  Our new approach leads us to examine these diseases through their similarities instead of differences.

How To Detect Alzheimer’s and Parkinson’s With Certainty?

Amprion’s Prion Early Detection Science aims to gather newfound knowledge of how and when ParkinZheimer starts in the human body, leading the path to finding a cure.

Chief Scientific Officer Claudio Soto discusses the science behind Amprion’s early detection testing for ParkinZheimer.

When Can I Get Amprion’s Early Detection Testing?

Our FDA Breakthrough Device Designation for detecting Misfolded Protein Synuclein, a biomarker related to Parkinson’s and a select group of Alzheimer’s patients, is expected to launch in selective markets in the first quarter of 2021.

If you’re interested in joining our priority list for testing, sign up below.

Want to learn more about Alzheimer’s or Parkinson’s? Click the links below. At Amprion, we respect your privacy and will only use these data for Amprion’s assessment for testing priorities.

At Amprion, we strive to crack the code on brain health, and we believe Alzheimer’s and Parkinson’s and other neurodegenerative diseases are all closely related. So close, they lie on the same spectrum: The ParkinZheimer Spectrum.

Read more about ParkinZheimer.

We’d love to hear from you.